Decent Q2 performance; 2025 guidance unchanged
01/08/25 -"DiaSorin reported satisfactory Q2 results, with sales growth across all segments and continued profitability improvements. Management reaffirmed the 2025 guidance. We maintain a positive ..."
Pages
65
Language
English
Published on
01/08/25
You may also be interested by these reports :
01/08/25
DiaSorin reported satisfactory Q2 results, with sales growth across all segments and continued profitability improvements. Management reaffirmed the ...
30/07/25
Clariane’s H1 25 results present a mixed picture. The group has improved its leverage, primarily due to the recent sale of Petits-Fils, which enabled ...
30/07/25
Siemens Healthineers’ Q3 results exceeded expectations. Top-line growth was driven by strong performances in Imaging and Varian, with Advanced ...
30/07/25
Drägerwerk’s Q2 2025 results aligned with preliminary figures, with net sales up 1.8% on a constant currency basis, as Medical (+5%) more than offset ...